Literature DB >> 9314220

Fifty years of plutonium exposure to the Manhattan Project plutonium workers: an update.

G L Voelz1, J N Lawrence, E R Johnson.   

Abstract

Twenty-six white male workers who did the original plutonium research and development work at Los Alamos have been examined periodically over the past 50 y to identify possible health effects from internal plutonium depositions. Their effective doses range from 0.1 to 7.2 Sv with a median value of 1.25 Sv. As of the end of 1994, 7 individuals have died compared with an expected 16 deaths based on mortality rates of U.S. white males in the general population. The standardized mortality ratio (SMR) is 0.43. When compared with 876 unexposed Los Alamos workers of the same period, the plutonium worker's mortality rate was also not elevated (SMR = 0.77). The 19 living persons have diseases and physical changes characteristic of a male population with a median age of 72 y (range = 69 to 86 y). Eight of the twenty-six workers have been diagnosed as having one or more cancers, which is within the expected range. The underlying cause of death in three of the seven deceased persons was from cancer, namely cancer of prostate, lung, and bone. Mortality from all cancers was not statistically elevated. The effective doses from plutonium to these individuals are compared with current radiation protection guidelines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314220     DOI: 10.1097/00004032-199710000-00004

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  8 in total

1.  Smoking and hormesis as confounding factors in radiation pulmonary carcinogenesis.

Authors:  Charles L Sanders; Bobby R Scott
Journal:  Dose Response       Date:  2006-12-06       Impact factor: 2.658

2.  Lung, liver and bone cancer mortality in Mayak workers.

Authors:  Mikhail E Sokolnikov; Ethel S Gilbert; Dale L Preston; Elaine Ron; Natalia S Shilnikova; Victor V Khokhryakov; Evgeny K Vasilenko; Nina A Koshurnikova
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

3.  Lung cancer risks from plutonium: an updated analysis of data from the Mayak worker cohort.

Authors:  E S Gilbert; M E Sokolnikov; D L Preston; S J Schonfeld; A E Schadilov; E K Vasilenko; N A Koshurnikova
Journal:  Radiat Res       Date:  2013-02-07       Impact factor: 2.841

4.  Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British Nuclear Fuels.

Authors:  R Z Omar; J A Barber; P G Smith
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

5.  Correction of confidence intervals in excess relative risk models using Monte Carlo dosimetry systems with shared errors.

Authors:  Zhuo Zhang; Dale L Preston; Mikhail Sokolnikov; Bruce A Napier; Marina Degteva; Brian Moroz; Vadim Vostrotin; Elena Shiskina; Alan Birchall; Daniel O Stram
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

6.  Risk of Lung Cancer Mortality in Nuclear Workers from Internal Exposure to Alpha Particle-emitting Radionuclides.

Authors:  James Grellier; Will Atkinson; Philippe Bérard; Derek Bingham; Alan Birchall; Eric Blanchardon; Richard Bull; Irina Guseva Canu; Cécile Challeton-de Vathaire; Rupert Cockerill; Minh T Do; Hilde Engels; Jordi Figuerola; Adrian Foster; Luc Holmstock; Christian Hurtgen; Dominique Laurier; Matthew Puncher; Anthony E Riddell; Eric Samson; Isabelle Thierry-Chef; Margot Tirmarche; Martine Vrijheid; Elisabeth Cardis
Journal:  Epidemiology       Date:  2017-09       Impact factor: 4.822

7.  Commentary on Inhaled (239)PUO2 in Dogs - A Prophylaxis Against Lung Cancer?

Authors:  Jerry M Cuttler; Ludwig E Feinendegen
Journal:  Dose Response       Date:  2015-05-04       Impact factor: 2.658

8.  Plutonium in Manhattan Project workers: Using autopsy data to evaluate organ content and dose estimates based on urine bioassay with implications for radiation epidemiology.

Authors:  Martin Šefl; Joey Y Zhou; Maia Avtandilashvili; Stacey L McComish; Sergei Y Tolmachev
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.